Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.54 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.54 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.54 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.54 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.54 |
| ▸ | FPR2 | P25090 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 4/20 | 0.52 |
| ▸ | CPA1 | P15085 | 3/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1833280 | 1.00 | MME (0.56) | MMENPSR1GPR132ITGB1ITGA4 | |
| SCHEMBL10974653 | 0.91 | MME (0.56) | MMEGPR132ITGB1ITGA4ITGB7 | |
| SCHEMBL2747735 | 0.89 | PPARG (0.65) | MMEGPR132ACECPA1ACE2 | |
| SCHEMBL2747442 | 0.87 | NAALAD2 (0.69) | MMENAALAD2SLC1A3 | |
| SCHEMBL1219647 | 0.85 | MEN1 (0.53) | ITGB1ITGA4ITGB7FPR2 | |
| SCHEMBL1219646 | 0.85 | MEN1 (0.53) | ITGB1ITGA4ITGB7FPR2 | |
| SCHEMBL30090841 | 0.85 | MME (0.61) | MMENPSR1GPR132NAALAD2FPR2 | |
| SCHEMBL28353707 | 0.85 | MME (0.61) | MMENPSR1GPR132NAALAD2FPR2 | |
| SCHEMBL16124629 | 0.84 | ACE (0.51) | MMEGPR132ITGB1ITGA4ITGB7 | |
| SCHEMBL16124607 | 0.84 | ITGB1 (0.55) | MMEITGB1ITGA4ITGB7FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024043313-A1 | REVERSIBLE THERMOCHROMIC COMPOSITION, MICROENCAPSULATED PIGMENT USING SAID REVERSIBLE THERMOCHROMIC COMPOSITION, WRITING TOOL, AND TOY | 三菱ケミカル株式会社 | 2024-02-29 | — | — | WO | disclosed |
| CN-115160187-A | Preparation method of N-benzyloxycarbonyl-L-phenylalanine | 山西百利恒康医药科技有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-112438905-B | Moisturizing and skin-brightening composition and application thereof | 澳思美日用化工（广州）有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-10968168-B2 | Isocyanate production method | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10968168-B2 | Isocyanate production method | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-04-06 | — | — | US | disclosed |
| EP-3626705-B1 | ISOCYANATE PRODUCTION METHOD | ASAHI CHEMICAL IND (JP) | 2021-03-24 | — | — | EP | disclosed |
| CN-112438905-A | Moisturizing and skin-brightening composition and application thereof | 澳思美日用化工（广州）有限公司 | 2021-03-05 | — | — | CN | disclosed |
| US-20200115327-A1 | ISOCYANATE PRODUCTION METHOD | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-04-16 | — | — | US | disclosed |
| US-20200115327-A1 | ISOCYANATE PRODUCTION METHOD | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-04-16 | — | — | US | disclosed |
| CN-102123994-A | N-carboxy amino acid anhydride and amino acid carbamate compound production method | JSR CORP | 2011-07-13 | — | — | CN | disclosed |
| EP-1338588-B1 | METHOD OF RESOLVING OPTICAL ISOMERS OF AMINO ACID DERIVATIVE | TOKUYAMA CORP (JP) | 2007-09-26 | — | — | EP | disclosed |
| US-7199264-B2 | Method of resolving optical isomers of amino acid derivative | TOKUYAMA CORPORATION (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040102646-A1 | Method of resolving optical isomers of amino acid derivative | TOKUYAMA CORPORATION (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1338588-A1 | METHOD OF RESOLVING OPTICAL ISOMERS OF AMINO ACID DERIVATIVE | TOKUYAMA CORPORATION (JP) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102646-A1 | Method of resolving optical isomers of amino acid derivative | ALAD, AAAS, BCAT1 | MME 1298/4885NPSR1 3306/4885GPR132 2707/4885 |
| US-20200115327-A1 | ISOCYANATE PRODUCTION METHOD | IDH3A, ALKBH3, CPS1 | MME 2353/4885NPSR1 4777/4885GPR132 4724/4885 |
| US-10968168-B2 | Isocyanate production method | IDH3A, ALKBH3, CPS1 | MME 2353/4885NPSR1 4777/4885GPR132 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.